Table 1.
Patient characteristics at baseline
| Placebo | Active treatment | Test for between-group differences | |
|---|---|---|---|
| N | 510 | 706 | |
| N Gender F (%) | 223 (44) | 335 (48) | χ2 = 1.5 (p 0.22) |
| N Gender M (%) | 287 (56) | 371 (52) | |
| Mean age (SD) | 37.7 (12) | 38.0 (12) | t = −0.38 (p 0.70) |
| Mean YBOCS (SD) | 24.6 (5.0) | 24.4 (4.8) | t = −0.57 (p 0.57) |
| Mild N | 141 | 182 | |
| Moderate N | 294 | 429 | |
| Severe N | 74 | 95 | |
| Median CGI–S (IQR) | 5 (1) | 5 (1) | W = 150908 (p 0.51) |
Note: p = probability value after t-test for numerical values (age, YBOCS), χ2 for dichotomous outcomes (gender) and Mann–Whitney U test (W-statistic) for categorical variables (CGI-S). N = number, SD = standard deviation, YBOCS = Yale-Brown Obsessive-Compulsive Scale, CGI-S = Clinical Global Impression – Severity. “Mild” = YBOCS 14–21, “Moderate” = YBOCS 22–29, “Severe” = YBOCS 30–40, according to empirical benchmarks by Cervin et al. [25].